CASI Pharmaceuticals, Inc.

CASI

KYG1933S1012

Pharmaceuticals

Delayed Nasdaq Other stock markets 16:34:33 16/07/2024 BST			5-day change	1st Jan Change
6.07 ^USD	-2.88%		-11.26%	-15.22%

07-08	CASI Pharmaceuticals Names Daniel Lang CFO	MT
07-08	CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO	CI

CASI PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)

January 28, 2021 at 09:04 pm

Item 8.01. Other Events.

On January 28, 2021, CASI Pharmaceuticals, Inc. (the "Company") announced that its partner, BioInvent International AB, released positive interim results from its Phase I/IIa trial that suggests that novel anti-FcyRIIB antibody BI-1206 restores activity of rituximab in relapsed non-Hodgkin's lymphoma patients. The Company's press release is attached to this Current Report on Form 8-K as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits




     Exhibit
     Number       Description

       99.1         Press Release of CASI Pharmaceuticals, Inc., dated January 28,
                  2021

     104          Inline XBRL for the cover page of this Current Report on Form
                  8-K

Latest news about CASI Pharmaceuticals, Inc.

CASI Pharmaceuticals Names Daniel Lang CFO	07-08	MT
CASI Pharmaceuticals, Inc. Appoints Daniel Lang as CFO	07-08	CI
CASI Pharmaceuticals, Inc. Appoints Daniel Lang as Senior Vice President	07-08	CI
Wall Street Set to Open Marginally Lower Thursday as Investors Parse Bullish Economic Data	06-27	MT
US Futures Trend Lower Pre-Bell as Investors Await Slew of Economic Data	06-27	MT
Top Premarket Gainers	06-27	MT
CASI Pharmaceuticals Announces Plan To Submit IND Application For CID-103, an Anti-CD 38 Antibody in Antibody-Mediated Rejection, and Receipt of a Non-Binding Proposal to Acquire Entire China Business of the Company	06-26	CI
Wei-Wu He proposed to acquire Business Operations in China and all license-in, distribution and related rights in Asia from CASI Pharmaceuticals, Inc. for $40 million.	06-25	CI
CASI Pharmaceuticals Receives Acquisition Proposal for its Entire China Business	06-25	CI
CASI Pharmaceuticals, Inc. announced that it expects to receive $15 million in funding from VR Adviser, LLC, Foresite Capital Management, LLC, Panacea Venture Management Co., Ltd.	06-25	CI
Sector Update: Health Care Stocks Advance in Afternoon Trading	05-15	MT
CASI Pharmaceuticals Gets FDA Clearance For Blood Disorder Study	05-15	MT
CASI Pharmaceuticals Receives FDA Clearance on the Investigational New Drug Application for CID-103 in Immune Thrombocytopenia	05-15	CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q1 Revenue $3.4M, vs. Street Est of $12M	05-14	MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Top Midday Gainers	03-05	MT
Looming Employment Report, Powell Testimony Stifle US Equity Futures Pre-Bell	03-05	MT
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday	03-05	MT
Top Premarket Gainers	03-05	MT
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China	03-05	CI
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd	02-29	CI
Casi Pharmaceuticals Announces First Dose of Folotyn in China	02-16	CI
CASI Pharmaceuticals, Inc. Announces Resignation of Fuqiang Zhang as Chief Commercial Officer	02-12	CI
CASI Pharmaceuticals, Inc. Appoints of Mr. Huang Hai as the Global Chief Commercial Officer	01-30	CI

Chart CASI Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its commercial product, EVOMELA, is an intravenous formulation of melphalan commercialized by Acrotech in the multiple myeloma treatment setting in the United States. Its pipeline products include CNCT19 (CD19 CAR-T), BI-1206 (anti- FcYRIIB antibody), CB-5339 (VCP/p97 inhibitor), CID-103 (Anti-CD38 Mab), Thiotepa, and Octreotide LAI. The Companyâs Food and Drug Administration (FDA)-approved generic products for the China market include Entecavir tablets, Tenofovir disoproxil fumarate (TDF) tablets, Cilostazol tablets-50mg, Cilostazol tablets-100mg, Ondansetron HCL tablets, and Tizanidine tablets.

Sector

Pharmaceuticals

Calendar

08/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CASI Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.25 USD

Average target price

6 USD

Spread / Average Target

-4.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
CASI PHARMACEUTICALS, INC.	-15.22%	81.18M
ELI LILLY AND COMPANY	+62.97%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-4.06%	359B
MERCK & CO., INC.	+16.14%	325B
ABBVIE INC.	+8.88%	297B
ROCHE HOLDING AG	+5.89%	234B
NOVARTIS AG	+16.53%	226B
AMGEN INC.	+15.61%	177B
PFIZER, INC.	+1.75%	165B

Other Pharmaceuticals